NodThera, a prominent biotech firm specialising in chronic inflammatory diseases, has appointed Daniel Swisher as its new Chief Executive Officer (CEO) to enhance the company’s commercial capabilities. Effective immediately, Swisher assumes leadership, while Alan Watt, the interim CEO and Company founder, transitions to President and Chief Scientific Officer (CSO).
With over 30 years of leadership experience in the pharmaceutical industry, Swisher brings a wealth of expertise to NodThera. Previously serving as President and Chief Operating Officer at Jazz Pharmaceuticals, Swisher played a pivotal role in expanding the company’s commercial and research pipeline. Prior to his tenure at Jazz, he served as CEO and President of Sunesis Pharmaceuticals, overseeing significant equity capital market fundraises and leading the company to an IPO on the Nasdaq stock exchange.
As Swisher takes the helm at NodThera, he aims to leverage the company’s pioneering work in NLRP3 inflammasome modulation to address chronic inflammatory diseases effectively. NodThera’s focus on neuroinflammation modulation for the treatment of obesity, cardiometabolic disease, and neurodegeneration aligns with Swisher’s vision to make a positive impact on patient lives.
Alan Watt, now President and CSO of NodThera, expressed confidence in the company’s research and development efforts, highlighting the potential for profound change in disease management. With Swisher’s leadership and the expertise of the NodThera team, the company is poised to advance its innovative treatments and deliver meaningful solutions to patients in need.
